A new company has been founded to provide much-needed support to industry, SMEs, startups and research groups developing nanopharmaceuticals. PHOENIX-OITB gGmbH, founded in November 2023, offers an “all-in-one” Single Entry Point to users, providing manufacturing, characterization, testing and innovation-related consulting services including regulatory and business guidance to accelerate maturity of nanopharmaceuticals and diagnostic agents.
With a strong vision to remove barriers to nanopharmaceutical innovation, PHOENIX offers affordable and easy access to a consolidated network of facilities, technologies, services and expertise from across Europe for all the technology transfer aspects, i.e., characterization, in vitro and in vivo testing, validation up to scale-up, regulatory guidance and GMP compliant manufacturing.
Customers contacting the PHOENIX Single Entry Point will be matched with a dedicated contact person to evaluate their needs. The customer will then be matched with relevant experts providing the desired services and obtain a comprehensive plan of services. The PHOENIX Single Entry Point portfolio is continuously updated based on customer and market needs. The PHOENIX network covers the entire supply chain from bench to bedside, as well as every administration route (e.g. oral, IV, dermal, etc.).
Available services are categorised within physico-chemical characterisation, in vitro charactertisation, in vivo characterisation, GMP manufacturing and innovation. A full description of comprehensive services will be added to this website later in 2024.
